Abstract
We disclose here a series of P4-benzoxaborole-substituted macrocyclic HCV protease inhibitors. These inhibitors are potent against HCV NS3 protease, their anti-HCV replicon potencies are largely impacted by substitutions on benzoxaborole ring system and P2∗ groups. P2∗ 2-thiazole-isoquinoline provides best replicon potency. The in vitro SAR studies and in vivo PK evaluations of selected compounds are described herein.
Copyright © 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Animals
-
Antiviral Agents / chemical synthesis*
-
Antiviral Agents / chemistry
-
Antiviral Agents / pharmacokinetics
-
Hepacivirus / enzymology*
-
Isoquinolines / chemistry
-
Macrocyclic Compounds / chemical synthesis
-
Macrocyclic Compounds / chemistry*
-
Macrocyclic Compounds / pharmacokinetics
-
Protease Inhibitors / chemical synthesis*
-
Protease Inhibitors / chemistry
-
Protease Inhibitors / pharmacokinetics
-
Rats
-
Structure-Activity Relationship
-
Thiazoles / chemistry
-
Viral Nonstructural Proteins / antagonists & inhibitors*
-
Viral Nonstructural Proteins / metabolism
Substances
-
Antiviral Agents
-
Isoquinolines
-
Macrocyclic Compounds
-
NS3 protein, hepatitis C virus
-
Protease Inhibitors
-
Thiazoles
-
Viral Nonstructural Proteins
-
isoquinoline